News | February 21, 2023
Teijin and Axcelead to establish drug discovery research JV
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
The new sterile filling line meets cGMP aseptic filling regulatory requirements
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States
Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
Subscribe To Our Newsletter & Stay Updated
